Actinium Pharmaceuticals Stock
Actinium Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sandesh C. Seth
- Employees
- 27
- Market cap
- $36 M
- IPO
- 27/12/2012
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in…
Actinium Pharmaceuticals stock: price history
1D
+6.6%
1W
+2.7%
1M
-8.9%
6M
-13.1%
YTD
-16.9%
1Y
-22.6%
2Y
-32.7%
5Y
-85.9%
10Y
-96.7%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~67% stronger price swings than usual
Ask the agents about Actinium Pharmaceuticals
Analyst assessment of Actinium Pharmaceuticals
PRICE TARGET LOW
US$4.00
CONSENSUS
US$11.07
MEDIAN
US$4.95
PRICE TARGET HIGH
US$24.26
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 31/03/2026
Actinium Pharmaceuticals stock metrics
P/E
3.14
P/B
1.17
EV/EBITDA
0.03
RETURN ON EQUITY
92.1%
NET MARGIN
79.7%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.4%
FLOAT SHARES
31,255,303
AVG. DAILY VOLUME (30D)
146,148
Insider transactions (SEC)
David Matthew T
Steinhart Richard I
SETH SANDESH
SETH SANDESH
Chell Jeffrey W.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Actinium Pharmaceuticals stock
What does Actinium Pharmaceuticals do?
Actinium Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sandesh C. Seth, the company employs around 27 people.
The IPO was on 27/12/2012; the stock trades on AMEX under the ticker ATNM.
What do analysts say about Actinium Pharmaceuticals stock?
11 analysts rate the stock, the consensus is Buy (as of 31/03/2026).
The average price target is US$11.07, ranging from US$4.00 to US$24.26, with a median of US$4.95.
This is an external assessment, not a statement by Market Jury.
When does Actinium Pharmaceuticals report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 67% stronger than usual.
Does Actinium Pharmaceuticals pay a dividend?
No, Actinium Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Actinium Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Actinium Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Actinium Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.